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Abstract 
 
Despite the established role of Ki67 labelling index in prognostic stratification of 
adrenocortical carcinomas and its recent integration into treatment flow charts, the 
reproducibility of the assessment method has not been determined. The aim of this 
study was to investigate inter-observer variability among endocrine pathologists using a 
web-based virtual microscopy approach. Ki67 stained slides of 76 adrenocortical 
carcinomas were analyzed independently by 14 observers; each according to their 
method of preference including eyeballing, formal manual counting and digital image 
analysis. The inter-observer variation was statistically significant (p<0.001) in the 
absence of any correlation between the various methods. Subsequently, 61 static 
images were distributed among fifteen observers who were instructed to follow a 
category-based scoring approach. Low levels of inter-observer (F=6.99; Fcrit= 1.70; 
p<0.001) as well as intra-observer concordance (n=11; Cohen’s Kappa ranging from -
0.057 to 0.361) were detected. To improve harmonization of Ki67 analysis, we tested 
the utility of an open source Galaxy virtual machine application, namely Automated 
Selection of Hotspots, in 61 virtual slides. The software-provided Ki67 values were 
validated by digital image analysis in identical images, displaying strong correlation 0.96 
(p<0.0001) and dividing the cases into 3 classes (cut-offs of 0%-15%-30% and/or 0%-
10%-20%) with significantly different overall survivals (p<0.05). We conclude that 
current practices in Ki67 scoring assessment vary greatly and inter-observer variation 
sets particular limitations to its clinical utility, especially around clinically relevant cut-off 
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values. Novel digital microscopy-enabled methods could provide critical aid in reducing 
variation, increasing reproducibility and improving reliability in the clinical setting. 
 
Key words or phrases: Ki67 labelling index; proliferation; adrenal cortical carcinoma; 
interobserver variation; digital pathology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Papathomas et al. 
7	
	
Introduction 
 
     Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with a poor overall 
prognosis and an estimated incidence of 0.7-2 cases per million (1). When confronted 
with this tumor, pathologists are expected to provide the Weiss score, the status of 
resection margins and prognosticators including the Weiss score, mitotic grade and 
Ki67 labelling index (LI), and, if diagnostically challenging, confirm its adrenocortical 
origin on immunohistochemical grounds (2-3). It has been shown (4) that ACCs can be 
subdivided using a variety of methods including the mitotic frequency into low-grade 
(≤20 mitoses/50 HPFs) and high-grade (>20 mitoses/50 HPFs) (5), Stereoidogenic 
Factor-1 immunohistochemistry (6-7) and other proliferation-based scoring methods 
such as phosphohistone H3–specific immunohistochemistry (8). 
     According to recent data generated by the European Network for the Study of 
Adrenal Tumors (ENS@T) ACC study group (9-10), the resection status and the Ki67 
labelling index in both localized and advanced ACCs constitute the most relevant 
prognostic parameters (2). In accordance, Duregon et al. (8) demonstrated that Ki67 LI 
is the most powerful tool in terms of prognostic stratification. In addition to its emerging 
value as a critical determinant of prognosis, Ki67 LI has been recently integrated in 
treatment flow charts for adrenocortical cancer patients suffering from tumors either 
amenable to radical resection or at advanced presentation. Accordingly, thresholds of 
10%, 20%, and 30% seem to be crucial in therapeutic decisions, including adjuvant 
mitotane, radiotherapy of the tumor bed as well as combination therapy of mitotane and 
three cycles of cisplatin respectively (1-2). 
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     The standardized assessment of Ki67 LI is important and remains a key issue and 
responsibility of histopathologists. Nevertheless, various factors, such as pre-analytical, 
analytical, interpretation, scoring, and data analysis, might affect the Ki67 LI (11). In 
particular, lack of uniformity and consistency in quantification (12) as well as 
intratumoral heterogeneity of proliferation (5, 11, 13-14) might limit its assessment. In 
this context, we have implemented an open source toolset, namely Automated 
Selection of Hotspots (ASH) aiming at improved accuracy and reproducibility of 
reporting of the Ki67 LI (15). 
     In the present study, we determined the inter-observer variability for Ki67 LI and 
examined the current practices among expert endocrine pathologists in a multicenter 
cohort of conventional ACCs using virtual microscopy. The impact of various 
parameters, i.e. readout technique of preference in diagnostics, selected fields for 
evaluation and estimated total number of cells, on Ki67 assessment was further 
investigated. Moreover, we evaluated the variability of Ki67 LI around clinically relevant 
cut-offs (1-2) and validated the efficiency of ASH as compared to the human 
independent selection of hotspot areas. 
 
Materials and Methods 
 
Case selection and KI67 (MIB1) immunohistochemistry 
     One hundred and one conventional ACCs were collected from four specialized 
centres from Europe and United States: (1) San Luigi Gonzaga Hospital and 
University of Turin, Turin, Italy (25 samples), (2) Erasmus MC Cancer Institute, 
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Rotterdam, The Netherlands (12 samples), (3) University of Wisconsin School of 
Medicine and Public Health (5 samples) and (4) University of Michigan Health 
System (59 samples). Borderline/ atypical adrenocortical neoplasms as well as ACC 
variants (oncocytic, myxoid and sarcomatoid) were not included in the present study. 
Each case was thoroughly reviewed and representative unstained glass slide(s) were 
selected and provided for immunohistochemical analysis within a single center 
(Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands) 
with the following protocol. Slides and formalin-fixed paraffin-embedded (FFPE) whole-
tissue sections of 4µm thickness were stained with a commercially available antibody: 
mouse monoclonal MIB1 M7240 antibody (Dako, Glostrup, Denmark; 1:400 dilution) 
against Ki67 on an automatic Ventana Benchmark Ultra System (Ventana Medical 
Systems Inc. Tuscon, AZ, USA) using Ultraview DAB detection system preceded by 
heat-induced epitope retrieval with Ventana Cell Conditioning 1 (pH 8.4) at 97◦C for 52 
minutes. Diaminobenzidine was used as the chromogen. All cases were assessed 
anonymously according to the Proper Secondary Use of Human Tissue code 
established by the Dutch Federation of Medical Scientific Societies (http:// 
www.federa.org). The Medical Ethical Committee of the Erasmus MC approved the 
study. Cases displaying artefactual intratumoral variation in labeling were excluded by 
use of Ki67 labeled mitotic figures as internal positive controls. 
 
Digital pathology application 
     High-resolution, whole-slide images were acquired from all Ki67 (MIB1) stained 
slides using a NanoZoomer Digital Pathology (NDP) System (Hamamatsu Photonics 
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K.K. Japan) working at a resolution of 0.23 µm/pixel. The immunostains were scanned 
at x40 magnification and automatically digitized in their proprietary NDP Image (NDPI) 
file format. Between October 2013 and March 2014, digital files were consecutively 
uploaded in one set to a server at Erasmus MC through the standard File transfer 
Protocol (FTP) in the DMZ with URL: http://digimic.erasmusmc.nl/; enabling online 
worldwide viewing through a virtual microscopy interface (NDP.view Viewer Software, 
Hamamatsu Photonics K.K. Japan). 
 
Participants and interpretation of staining results 
     In the first round (Supplemental Digital Content 1), fourteen observers, among 
which 11 expert endocrine pathologists (R.V.L., L.E., V.N., O.M., S.L.A., X.G., T.J.S., 
K.S., F.T., F.H. vanN., R.R.deK.) and 3 residents (T.G.P., E.D. & J.T) received: (i) an 
email detailing the objectives of the project and clearly stating that only nuclear staining 
(plus mitotic figures which are stained by Ki67) should be incorporated into the Ki67 
score defined as the percentage of positively stained cells among the total number of 
malignant cells scored with staining intensity being of no relevance (11), (ii) the 
corresponding link providing access to the virtual slides, and (iii) a scoring list to be 
completed during Ki67 immunohistochemical evaluations. 
     All virtual slides were distributed online, reviewed by each observer in a blinded 
fashion without knowledge of the corresponding clinicopathological data or scores 
assigned by other pathologists. In particular, participants were asked to assess (i) the 
Ki67 LI based on (ii) the method of their preference/practice in diagnostics (visual 
estimation, formal manual count or Digital Image Analysis [DIA]) reporting on (iii) the 
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estimated total number of cells and (iv) the selected fields for evaluation i.e. hot spot 
area(s) or average score across the section, or average score across the section adding 
hot spot area(s). 
     Twenty-five cases were excluded from the analysis due to subtoptimal staining, poor 
scan quality and fixation artifacts. The remaining tumors from 76 patients of mean age 
47.6 years (ranging from 8 to 85 years; 1.17 female:male ratio) comprised 62 primary 
tumors, 6 recurrences and 8 metastases. Thirty-four patients died of the disease, while 
42 are alive with or without evidence of disease. The latter are currently in follow-up at 
various institutions with a mean of 34.27 months (range, 1 week to 169 months).  
     In the second round of assessment performed 9 months later (Supplemental Digital 
Content 1), 61 static images (.JPG files) were circulated among 15 observers, including 
11 expert endocrine pathologists (R.V.L., L.E., O.M., S.L.A., T.J.S., K.S., M.V., A.S.T., 
A.J.G., F.H. vanN., R.R.deK.) and 4 residents (T.G.P., E.P., E.D. & J.T). These images 
were selected as the most active areas based on an automated approach (15). The 
participants were instructed to follow a category-based evaluation of the Ki67 LI on the 
basis of visual estimation without performing formal manual count or DIA. 
 
Software application 
     Seventy-six virtual slides were assessed with a recently developed open source 
Galaxy virtual machine application designed for Ki67 hotspot detection in adrenocortical 
cancer (Supplemental Digital Content 1). In brief, ASH comprises three classes: NDPI 
Segmentation, Adaptive Step Finding and a Reporting Visualization which utilizes the 
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NDPI splitter to convert the specific NDPI format digital slide into a conventional tiff or 
jpeg format image for automated segmentation and adaptive step finding hotspots 
detection algorithm (15). Quantitative hotspot ranking is provided by the functionality 
from the open source application ImmunoRatio (16) as part of the ASH protocol. 
Accordingly, the output is a ranked set of hotspots with concomitant quantitative values 
based on whole slide ranking. 
 
Statistical analysis 
     Inter-observer variability using either virtual microscopy (first evaluation) or visual 
estimation on static images (second evaluation) as well as differences in the type of 
assessment was assessed with ANOVA single factor. In order to evaluate intra-
observer agreement, Cohen’s Kappa was performed following conversion of the Ki67 
values of the initial numerical assessment into categorical variables. With regard to 
automatically selected areas, we compared computerized counts based on 
ImmunoRatio and DIA respectively in identical images using Pearson correlation with 
“Wessa, P. (2015), Free Statistics Software, Office for Research Development and 
Education, version 1.1.23-r7, URL http://www.wessa.net/”. The correlation between 
human independent selection and software selection of hotspot areas was examined 
with Spearman rank order correlation. To compare the results of Ki67 assessment with 
overall survival, Kaplan-Meier curves were plotted and P values were calculated using 
the Log-rank test. The level of significance was set at P<0.05. All other statistical 
analyses were performed using SPSS software (SPSS version 21; SPSS, Inc., Chicago, 
IL, USA). 
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Results 
 
Inter-observer variation in KI67 LI assessment 
     Seventy-six cases were initially analyzed displaying statistically significant variance 
between 14 observers (ANOVA F= 10.43; Fcrit= 1.73; p<0.001) (Fig. 1). Differences in 
current practices concerning the Ki67 LI assessment are highlighted in Figure 2. Out of 
14 observers, eight preferred formal manual counting, four visual estimation and two 
DIA (ImageJ software, 1.47v, Wayne Rasband, NIH, USA &KS400 image analysis 
software, version 3.0, Carl Zeiss Vision GmbH). With regard to the residents, two used 
formal manual count and one DIA (KS400 image analysis software, version 3.0, Carl 
Zeiss Vision GmbH). The overall agreement was not affected by different levels of 
experience in endocrine pathology (data not shown). No statistical significance was 
found between the different methods of assessment (ANOVA p=0.079), except between 
visual estimation and formal manual count (t-test p=0.014). Kaplan-Meier curves based 
on overall survival were plotted against 0%-15%-30% cut-offs (Fig. 3).  
 
Impact of visual estimation on variation 
     Given the large variation observed in the initial Ki67 assessment, we decided to 
reduce potential complexities by using visual estimation and following a category-based 
approach in 61 pre-determined images. In this context, the variation remained 
statistically significant between 15 observers (ANOVA F=6.99; Fcrit= 1.70; p<0.001). In 
order to evaluate inter-observer concordance, ASH maximum values were utilized as 
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"gold standard" and transformed into categorical variables. The highest levels of 
concordance were achieved within the lowest range of Ki67 values i.e. 0-10% (Fig. 4). 
Likewise, the overall agreement was not affected by different levels of experience in 
endocrine pathology (data not shown).  In order to assess intra-observer concordance, 
we transformed those numerical values of the initial assessment into categorical 
variables. A very low degree of concordance was detected for every observer (n=11) 
(Supplemental Digital Content 2) with the majority having a higher score on visual 
estimation of pre-determined images (Fig. 5). 
 
Automated Selection of Hotspots (ASH): a virtual microscopy-enabled 
assessment of KI67 LI 
     Following software assessment, fifteen out of 76 cases were excluded due to 
artifacts interfering with the analysis. In order to verify its applicability in the remaining 
61 cases, we determined the degree of concordance (i) between computerized counts 
as provided by the software (ImmunoRatio) and by DIA (KS400 image analysis 
software, version 3.0, Carl Zeiss Vision GmbH) in identical images (n=610; 10 images 
as selected by the ASH per virtual slide); and (ii) between computerized counts as 
provided by the software (ImmunoRatio) and as generated by human independent 
selection (DIA) in different images displaying the highest Ki67 expression (n=61; 1 
image per virtual slide). To this end, an observer (T.G.P.) selected 10 hotspot areas by 
visual estimation on a virtual microscopy interface and subsequently performed DIA 
(KS400 image analysis software, version 3.0, Carl Zeiss Vision GmbH). In this setting, 
strong correlations of 0.96 and 0.84 were detected respectively (p<0.001). From a 
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clinical standpoint, we determined whether software-provided Ki67 values could divide 
the cases into 3 classes with significantly different overall survivals. In fact, when overall 
survival Kaplan-Meier curves were plotted against 0%-15%-30% and/or 0%-10%-20% 
cut-offs (Fig. 6), overall comparisons were statistically significant (p<0.05). 
 
Discussion 
 
     Ki67 immunohistochemistry has been integrated in routine pathology practice not 
only in diagnostics i.e. grading and tumor classification, diagnosis of intraepithelial 
neoplasia and assessment of malignant potential, but also as a prognostic and 
predictive biomarker. With regard to adrenocortical carcinomas, it has been proposed in 
diagnostics (17-18), prognostics (8-10, 19) as well as in guiding treatment decisions (1-
2). The current study highlights the need for standardized use of the Ki67 LI 
discouraging visual estimation and verifies the applicability of ASH in Ki67 assessment. 
     A large variation was noted among 14 observers in Ki67 index determination using a 
virtual microscopy interface. Because of the stringent centralized staining protocol, all 
participants were seeing the same slides. The variation therefore could not be explained 
by technical issues and had to be attributed to different practices with respect to 
interpretation and scoring such as area(s) of slide read, total number of cells in fields of 
evaluation and methods of assessment (11). In support of the last, we still observed 
significant levels of variation even when reducing complexities by estimating Ki67 LI 
levels in pre-selected areas and following a category-based approach using visual 
estimation. This is consistent with studies in breast carcinomas using a TMA platform 
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(20) as well as in gastroenteropancreatic neuroendocrine tumors using pre-determined 
images (12).  
     Although visual estimation has been suggested as an acceptable method of 
assessment on expert diagnostic (13) and/or research grounds (21-23), our findings 
further reinforce the notion that this readout technique is subjective, inaccurate and thus 
unreliable (12, 20, 24-25). Importantly, low levels of concordance were revealed around 
categorical cut-off values recently proposed in ACCs. This is in keeping with Tang et al. 
(12) who reported significant discordance among 18 observers, which was sufficient to 
alter the final grade of the majority of 45 neuroendocrine tumors. Whether such 
discordances could be solely ascribed to the method of assessment or partly to 
parameters residing in the realm of cognitive psychology (21) remains uncertain. 
     The aforementioned data challenge the clinical applicability of clinically relevant cut-
offs in ACCs. In accordance with Polley et al. (20) and Mengel et al. (26), Beuschlein et 
al. (9) suggested that Ki67LI  variability is to be expected in ACCs at different clinical 
centers highlighting the issue of inter-laboratory variation due to pre-analytical and 
analytical parameters (20, 26). In this setting, rigorous methods in tissue preparation, 
i.e. fixation, processing and generation of uniform sections, would seem to be important.  
Inter-laboratory variables at play, e.g. variation affecting controlled conditions, variability 
in microtomes used as well as differences in the temperature of the FFPE blocks, might 
have affected the thickness of the immunostained sections in the current study. In 
addition to the inter-laboratory variation, inter-observer and intra-observer variation (12, 
21, 27-28) and tumor heterogeneity of Ki67 expression levels (13-14, 29-30) seem to 
add further levels of complexity to the issue of reproducibility, thereby hampering its 
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clinical utility. This issue was emphasized by the International Ki67 in Breast Cancer 
Working Group (11) that was unable to reach a consensus in the absence of 
harmonized methodology with respect to ideal thresholds that could be useful in clinical 
routine practice. Accordingly, they recommended that cut-offs for prognosis, prediction, 
and monitoring should be applied only if the results from local practice have been 
validated against the respective ones in studies that have defined these particular cut-
offs (11, 20). 
     Various approaches have been developed to obtain standardized Ki67 scoring. 
These include efforts to reduce inter-laboratory variation by calibrating to a common 
scoring method via a web-based tool (31), and efforts to reduce inter- and intra-
observer variation by either selecting the most representative tumor areas based on an 
automated approach (15, 32-33) or providing a software-automated quantitation of Ki67 
LI (16, 34-36). In the setting of computerized image analysis, we verified the 
applicability of a digital microscopy-enabled method for assessment of Ki67 expression 
in adrenocortical cancer. The novel approach of software-selected areas aims not only 
to reduce the inter-observer variation, but also to characterize Ki67 levels of 
heterogeneity in primary tumors, recurrences and metastases. 
     User interaction is recommended prior to virtual slide analysis in order to ensure that 
areas leading to miscalculations, i.e. intrinsic as well as extrinsic pigmentation (deposit 
artifacts), necrotic areas, tissue folds etc, are excluded (15). In this series, excluding 
certain tissue regions was not sufficient to avoid serious miscalculations with regard to 
fifteen cases (15 out of 76; 20%) that were subsequently excluded from the analysis, 
calling into question potential clinical actions based on such cases. Future efforts should 
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focus on software amendments to overcome technical shortcomings in addition to 
improving methods of scoring.  
     In conclusion, current practices in Ki67 scoring assessment vary greatly and inter-
observer variation sets particular limitations to the clinical utility of Ki67 LI, especially 
around clinically relevant cut-off values, in adrenocortical cancer.  Our results highlight 
the need for standardization and suggest that visual estimation should be strongly 
discouraged as a readout technique, while computerized DIA appears to provide a 
reliable alternative. To drive forward harmonization of Ki67 analysis, we have previously 
developed and now validated an open source Galaxy virtual machine application, 
namely Automated Selection of Hotspots. Given certain pre-analytical and analytical 
concerns, quality assurance schemes i.e. standardized tissue fixation along with fine-
tuned immunohistochemical staining protocols are expected to additionally increase 
reproducibility and reliability of the Ki67 LI  in endocrine pathology practice. 
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Figure Legends 
 
Figure 1. Ki67 Labelling Index determined by14 observers on 76 Virtual Slides with 
various method of assessment. Ki67 was quantified as percentage of positive 
immunoreactive tumor cells against total tumor cells and was expressed as mean. 
 
Figure 2. Observers’ evaluation as referred to the method of assessment, fields of 
evaluation and total number of cells utilized in the count. 
 
Figure 3. Overall survival for DIA-MC performers (A), best performer (B), eyeballers (C) 
and all pathologists (D) using 0%-15%-30% as cut-offs.  
 
Figure 4. Levels of concordance between observers following a category-based Ki67 
scoring by visual estimation. 
 
Figure 5. Intra-observer concordance of 11 observers participating both in numerical 
and category-based assessment of the Ki67 Labelling Index (= equal > higher < lower 
score on visual estimation of pre-determined images). 
 
Figure 6. Overall survival determined by pathologists using 0%-15%-30% (A) and 0%-
10%-20% (B) cut-offs compared to the software (ASH) cut-off ranges of 0%-15%-30% 
(C) and 0%-10%-20% (D) respectively.  
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Supplemental Digital Content 
 
Supplemental Digital Content 1. Flowchart illustrating various steps of analysis 
through the study. 
 
Supplemental Digital Content 2. Intra-observer variability as evaluated by Cohen’s 
Kappa for 11 observers participating both in numerical and category-based assessment 
of the Ki67 Labelling Index (number of observations with = equal and/or > higher and/or 
< lower score on visual estimation of pre-determined images) 
 
 
 
